X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs CIPLA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA CIPLA SUN PHARMA/
CIPLA
 
P/E (TTM) x 27.6 34.7 79.7% View Chart
P/BV x 2.9 3.1 92.8% View Chart
Dividend Yield % 0.4 0.5 80.3%  

Financials

 SUN PHARMA   CIPLA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
CIPLA
Mar-18
SUN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs701663 105.7%   
Low Rs433479 90.4%   
Sales per share (Unadj.) Rs110.4189.0 58.4%  
Earnings per share (Unadj.) Rs11.017.6 62.4%  
Cash flow per share (Unadj.) Rs17.234.0 50.6%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.40.5 67.2%  
Book value per share (Unadj.) Rs158.8176.7 89.9%  
Shares outstanding (eoy) m2,399.26805.12 298.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.13.0 170.0%   
Avg P/E ratio x51.632.5 159.1%  
P/CF ratio (eoy) x32.916.8 196.1%  
Price / Book Value ratio x3.63.2 110.5%  
Dividend payout %18.217.1 106.9%   
Avg Mkt Cap Rs m1,360,021459,724 295.8%   
No. of employees `00017.823.6 75.3%   
Total wages/salary Rs m53,67126,901 199.5%   
Avg. sales/employee Rs Th14,890.96,446.1 231.0%   
Avg. wages/employee Rs Th3,017.11,139.4 264.8%   
Avg. net profit/employee Rs Th1,480.6600.0 246.8%   
INCOME DATA
Net Sales Rs m264,895152,193 174.1%  
Other income Rs m8,3883,577 234.5%   
Total revenues Rs m273,282155,769 175.4%   
Gross profit Rs m56,08128,264 198.4%  
Depreciation Rs m14,99813,228 113.4%   
Interest Rs m5,1761,142 453.1%   
Profit before tax Rs m44,29517,470 253.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m-9,505-775 1,226.1%   
Tax Rs m8,4522,501 337.9%   
Profit after tax Rs m26,33814,166 185.9%  
Gross profit margin %21.218.6 114.0%  
Effective tax rate %19.114.3 133.3%   
Net profit margin %9.99.3 106.8%  
BALANCE SHEET DATA
Current assets Rs m316,359108,141 292.5%   
Current liabilities Rs m198,64338,322 518.4%   
Net working cap to sales %44.445.9 96.9%  
Current ratio x1.62.8 56.4%  
Inventory Days Days9597 97.7%  
Debtors Days Days10874 144.7%  
Net fixed assets Rs m213,178109,411 194.8%   
Share capital Rs m2,3991,610 149.0%   
"Free" reserves Rs m378,606140,682 269.1%   
Net worth Rs m381,006142,292 267.8%   
Long term debt Rs m17,72136,621 48.4%   
Total assets Rs m643,028228,606 281.3%  
Interest coverage x9.616.3 58.7%   
Debt to equity ratio x00.3 18.1%  
Sales to assets ratio x0.40.7 61.9%   
Return on assets %4.96.7 73.2%  
Return on equity %6.910.0 69.4%  
Return on capital %10.010.0 100.7%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81651,691 79.0%   
Fx outflow Rs m30,14321,033 143.3%   
Net fx Rs m10,67330,658 34.8%   
CASH FLOW
From Operations Rs m39,07214,628 267.1%  
From Investments Rs m-33,708-8,540 394.7%  
From Financial Activity Rs m-15,393-3,855 399.3%  
Net Cashflow Rs m-7,3592,431 -302.7%  

Share Holding

Indian Promoters % 63.7 16.0 398.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.1 12.2 42.0%  
FIIs % 23.0 23.7 97.0%  
ADR/GDR % 0.0 1.1 -  
Free float % 8.3 26.2 31.7%  
Shareholders   133,026 161,166 82.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  GSK PHARMA  ALEMBIC PHARMA  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 324 Points Lower; Metal and Telecom Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Apr 25, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS